8-K: Pure Bioscience Secures $555K Private Placement

Pure Bioscience, Inc. has completed a private placement financing, raising $555,000 through the issuance of common stock at $0.0545 per share.

Summary

• Pure Bioscience, Inc. completed a private placement financing on October 15, 2026, raising $555,000.
• The company issued 10,183,486 shares of common stock at a purchase price of $0.0545 per share.
• A significant portion of the investment, $555,000, was made by Board member Tom Y. Lee and his affiliates.
• Net proceeds are expected to be approximately $555,000 after expenses.
• Funds will be used for general corporate purposes, including R&D, administrative expenses, and working capital.
• The shares were issued under an exemption from registration pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative development due to the dilutive nature of the financing and the low per-share price, although it provides necessary working capital.

Positives

• Secured $555,000 in new capital, providing essential funding for operations.
• Investment from a Board member (Tom Y. Lee) and affiliates may signal confidence in the company's prospects.
• Financing provides funds for research and development, general administrative expenses, and working capital.

Negatives

• The financing was conducted at a low per-share price of $0.0545, indicating potential dilution for existing shareholders.
• The issuance of over 10 million shares represents a significant increase in the total number of shares outstanding.
• The company relied on an exemption from registration, suggesting limitations in accessing public markets for capital.

Risks

• The shares issued may not be offered or sold in the United States without registration or an applicable exemption.
• Potential for further dilution if additional capital is needed and raised at similar or lower valuations.

Future Outlook

The company expects to use the net proceeds for general corporate purposes, including research and development efforts, general administrative expenses, and working capital.

Industry Context

StockSavvy.ai notes that private placements are a common method for early-stage or development-stage companies to raise capital when public market access is limited or unfavorable. The low per-share price suggests the company may be facing financial pressures or seeking to quickly secure funds for its operations and R&D in the competitive antimicrobial sector.

Related Party Transactions

• Mr. Tom Y. Lee, a member of the Board of Directors, invested $555,000 directly and through his affiliates.

Stakeholder Impact

• Existing shareholders may experience dilution due to the issuance of a significant number of new shares at a low price.
• The capital infusion is expected to support ongoing operations and R&D, potentially benefiting long-term value creation.

Next Steps

• Utilize net proceeds for general corporate purposes, including R&D, administrative expenses, and working capital.

Key Dates

Recommendation

The financing provides necessary liquidity for operations and R&D, which is positive. However, the low per-share price and significant dilution are concerning. A 'hold' recommendation reflects the balance between immediate operational support and potential long-term shareholder value erosion.

Keywords

private placement, financing, common stock, antimicrobial, working capital, research and development, accredited investors, securities purchase agreement